Table 2.
Serial analysis results of CTC counts, blood mutation load (BML), plasma EBV and imaging for 21 metastatic NPC patients.
| Patients | # CTC samples | CTC | EBV (copies/ml) | Imaging | CTC count | # mutations | BML (#/Mb)a | PFS (months) |
|---|---|---|---|---|---|---|---|---|
| 1 | 3 | 1 | 7838542 | PET1 | 1 | – | – | |
| 3 | 102813 | PET2: PMR | 4 | – | – | |||
| 4 | 172708 | PET3: SMD | 11 | – | – | Yes (4) | ||
| 1 | 24958 | PET1 | NA | – | – | |||
| 2 | 4 | 2 | 386 | 0 | – | – | ||
| 3 | 452 | PET2:PMR | NA | – | – | |||
| 4 | 428 | PET3:SMD | 2 | 25 | 3.6 | Yes (5) | ||
| 3 | 4 | 1 | 173958 | PET1 | 0 | – | – | |
| 2 | 86094 | 0 | – | – | ||||
| 3 | 41615 | PET2: SMD | 1 | – | – | |||
| 4 | 15896 | PET3: PMD | 2 | 66 | 9.4 | Yes (5) | ||
| 4 | 4 | 1 | 10895471 | PET1 | 2 | – | – | |
| 2 | 1191406 | 7 | – | – | ||||
| 3 | 33203125 | PET2: PMR | 2 | – | – | |||
| 4 | 27791667 | PET3: PMD | 4 | 3 | 0.4 | Yes (5) | ||
| 5 | 4 | 1 | 394636 | PET1 | 3 | – | – | |
| 2 | 3268 | 18 | – | – | ||||
| 3 | 3825 | PET2: PMR | 2 | – | – | |||
| 4 | 3922 | PET3: PMD | 2 | 113 | 16.1 | Yes (5) | ||
| 6 | 4 | 1 | 7109375 | PET1 | 5 | – | – | |
| 2 | 156458 | 2 | – | – | ||||
| 3 | 385417 | PET2: PMR | 1 | – | – | |||
| 4 | 367083 | PET3: PMD | 2 | 25 | 3.6 | Yes (5) | ||
| 7 | 4 | 1 | 34740 | PET1 | 1 | – | – | |
| 2 | 41 | 0 | – | – | ||||
| 3 | 102 | PET2: PMR | 0 | – | – | |||
| 4 | 2271 | PET3: PMD | 1 | 100 | 14.3 | Yes (6) | ||
| 8 | 4 | 1 | 504167 | PET1 | 8 | – | – | |
| 2 | 1103 | 5 | – | – | ||||
| 3 | 654 | PET2: PMR | 4 | – | – | |||
| 4 | 2217 | PET3: PMD | 0 | 129 | 18.4 | Yes (4) | ||
| 1 | 52792 | PET1 | 3 | – | – | |||
| 9 | 4 | 2 | 4879 | 4 | – | – | ||
| 3 | 812 | PET2:PMR | 8 | – | – | |||
| 4 | 1121 | PET3:PMD | 18 | 38 | 5.4 | Yes (5) | ||
| 10 | 4 | 1 | 42396 | PET1 | 3 | – | – | |
| 2 | 0 | 1 | – | – | ||||
| 3 | 27 | PET2: PMR | 0 | – | – | |||
| 4 | 0 | PET3: PMR | 2 | (a) 222 | 31.7 | Yes (11) | ||
| (b) 267 | 38.1 | |||||||
| 11 | 4 | 1 | 75542 | PET1 | 5 | – | – | |
| 2 | 109 | 8 | – | – | ||||
| 3 | 19 | PET2: PMR | 2 | – | – | |||
| 4 | 2329 | PET3: PMR | 4 | 46 | 6.6 | Yes (12) | ||
| 12 | 4 | 1 | 1204 | PET1 | 0 | – | – | |
| 2 | 0 | 0 | – | – | ||||
| 3 | 0 | PET2: PMR | 0 | – | – | |||
| 4 | 0 | PET3: PMR | 0 | 21 | 3 | Yes (25) | ||
| 1 | 94 | PET1 | 0 | – | – | |||
| 13 | 4 | 2 | 15 | 5 | – | – | ||
| 3 | 0 | PET2:SMD | 8 | – | – | |||
| 4 | 0 | PET3:PMR | 5 | – | – | No (15) | ||
| 14 | 5 | 1 | 341146 | PET1 | 0 | – | – | |
| 2 | 50 | 1 | – | – | ||||
| 3 | 166 | PET2: PMR | 0 | 113 | 16.1 | |||
| 4 | 7 | PET3: CMR | 2 | 75 | 10.7 | Yes (10) | ||
| 5 | 963 | 1 | 78 | 11.1 | ||||
| (b) 46 | 6.6 | |||||||
| 15 | 4 | 1 | 123958 | PET1 | 0 | – | – | |
| 2 | 86 | 0 | – | – | ||||
| 3 | 0 | PET2: PMR | 1 | – | – | |||
| 4 | 0 | PET3: CMR | 1 | 3 | 0.4 | Yes (24) | ||
| 16 | 4 | 1 | 399583 | PET1 | 0 | – | – | |
| 2 | 288 | 0 | – | – | ||||
| 3 | 648 | PET2: PMR | – | – | – | |||
| 4 | 119 | PET3: CMR | 4 | – | – | Yes (8) | ||
| 17 | 4 | 1 | 20427 | PET1 | 2 | – | – | |
| 2 | 0 | 0 | – | – | ||||
| 3 | 0 | PET2: CMR | 0 | – | – | |||
| 4 | 53 | PET3: CMR | 0 | 40 | 5.7 | Yes (9) | ||
| 18 | 4 | 1 | 40818 | PET1 | 2 | – | – | |
| 2 | 93 | 0 | – | – | ||||
| 3 | 11 | PET2: CMR | 0 | – | – | |||
| 4 | 0 | PET3: CMR | 0 | 2 | 0.3 | No (28) | ||
| 19 | 4 | 1 | 899 | PET1 | 0 | – | – | |
| 2 | 0 | 4 | – | – | ||||
| 3 | 0 | PET2: CMR | 0 | – | – | |||
| 4 | 0 | PET3: CMR | 0 | 160 | 22.9 | No (17) | ||
| 1 | 165 | PET1 | 0 | – | – | |||
| 20 | 3 | 2 | 666 | 0 | – | – | ||
| 3 | – | PET2:CMR | – | – | – | No (30) | ||
| 4 | 35 | PET3:CMR | 0 | – | – | |||
| 1 | 230417 | PET1 | 0 | – | – | |||
| 21 | 4 | 2 | 217 | 0 | – | – | ||
| 3 | 0 | PET2:CMR | 1 | – | – | |||
| 4 | 4 | PET3:CMR | 2 | – | – | No (18) |
PET1, PET2 and PET3 refer to the baseline, middle (before 3rd cycle) and end of treatment, respectively. The high purity runs for CTC enrichment of patients 1, 13, 16, 20 and 21, were not applicable for NGS analysis. Sufficient blood samples were available for duplicate BML analysis for patients 10 and 14.
aBML > 0.57 is defined as positive (four mutations were set as the cut-off in 7 Mb capture regions in the cell line spike-in experiment).
Patient died were shown as bold values in the table.